Healthcare Global Enterprises Ltd Q1 FY2025 Concall Summary

Key Takeaways

• All-time high revenue, 17% growth: HCG centers (ex-fertility) hit ₹511 crore, driven by strong volumes and a 12% ARPOB increase, while the Kolkata turnaround delivered a 73% YoY revenue surge into profitability.
• Vizag acquisition creates a 46% market-share leader: The ₹414 crore buy of MG Hospital, a 35% EBITDA-margin asset, consolidates HCG’s position as the undisputed leader in Vizag, with no additional capex needed.
• Operating leverage story is intact: ALOS dropped below the 2.0 target to 1.98, creating capacity, while established centers grew 14% and emerging centers grew 33%, setting up a guided 19-20% full-year EBITDA margin for the existing business.
• International business hits a record: At ₹20 crore, the quarter was the highest ever, nearly double pre-COVID levels, with a four-city hub strategy now bearing fruit after years of investment.
• What to watch next quarter: The pace of the guided 5-6% sequential Q2 revenue jump, the consolidation and margin impact of MG Hospital, and any concrete timeline for the primary issuance meant to deleverage the balance sheet.

The Vizag Consolidation: MG Hospital Acquisition

• The asset: MG Hospital is a 200-bed, net-debt-free, comprehensive cancer care provider with a ~30% standalone market share, a 35% EBITDA margin, over 30% pre-tax ROCE, and roughly 70% cash flow conversion from EBITDA.
• The combined entity: HCG’s existing Vizag center plus MG Hospital will command a 46% market share in the region, which management expects to grow 10-12% going forward. The combined equipment base will include four linear accelerators, two PET scans, and one robotic unit.
• No integration capex required: MG Hospital is already fully equipped with a robotic unit, PET scan, and linear accelerators; management stated no additional capex is planned for the next several years.
• Deal structure and leverage: The acquisition will initially add ₹200 crore of debt upon completion, with another ₹150 crore due after 18 months for the full 85% stake. Management has internally set a target debt-to-EBITDA ceiling of 2.5x to 2.75x on a pre-Ind AS basis and intends to seek board approval for a primary issuance to bring debt down significantly, though the timing remains open-ended.

Raj Gore: "We believe that the acquisition of MG Hospital will consolidate our market share in Vizag, positioning us as the undisputed leader in the region with a combined market share of 46%, promising significant synergy and growth potential ahead."

Existing Business Performance

• Revenue engine: HCG centers (excluding fertility) delivered all-time high revenue of ₹511 crore, 18% YoY growth adjusted for the discontinued MSR Bangalore center. Established centers grew 14%, while the three remaining emerging centers (Borivali, Colaba, Kolkata) grew 33% YoY.
• Kolkata turnaround: The Kolkata center swung from a ₹2.5 crore EBITDA loss in Q1 FY24 to a positive ₹2.7 crore EBITDA, a 14% margin, on 73% YoY revenue growth. This was a material contributor to the reduced losses in subsidiaries that improved the effective tax rate.
• Operational leverage in motion: ALOS fell from 2.13 to 1.98, driven by a focus on minimally invasive and robotic surgeries and the day-care nature of radiation oncology. This freed capacity and helped lift ARPOB by 12% YoY. OPD footfalls rose 10%, chemotherapy sessions grew 17%, and LINAC utilization held at 65% despite four new LINAC additions.
• Milann drag: Fertility revenue dipped 12% to ₹14.4 crore due to the discontinued Delhi center, a small but persistent headwind within the consolidated numbers.

Dr. B. S. Ajaikumar: "That is our target to be below two. And I think we have achieved it and will continue to pursue this matter the way we have done. That is a mark of excellence in my opinion."

Margin Trajectory and Profitability

• Q1 EBITDA: Adjusted EBITDA grew 21% YoY to ₹93 crore, with the salary revision impact absorbed in the quarter as expected. PAT rose 59% to ₹12 crore, though loss-making subsidiaries still weigh on the bottom line.
• Full-year guidance for the existing business: Management guided to a 19-20% EBITDA margin for the existing business (excluding the Vizag acquisition) for the full year, with established center growth expected in the 13-15% range.
• Emerging center margin unlock: The three emerging centers have now maintained positive EBITDA for over four quarters. Management expects substantive operating leverage and better margins over the next 12 months as revenues scale, with the South Mumbai center on track to break even this year.
• ETR benefit ahead: The effective tax rate for the quarter was 28.2%, helped by reduced losses in Kolkata, Nagpur, and Vadodara. Management expects the ETR to stay around 28% and sees further PAT enhancement as the remaining loss-making subsidiaries turn profitable.
• Finance cost pressure: Finance costs rose due to new right-of-use assets (Ahmedabad, North Bangalore, Kolkata renewals), roughly ₹50 crore of the ₹80 crore quarterly capex being debt-funded, and a ₹2.5 crore benefit reversal from Q4 FY24.

International Business and New Initiatives

• Record quarter: International business generated ₹20 crore, the highest for any quarter and nearly double the pre-COVID run rate. The four-city hub strategy (Bangalore, Mumbai, Kolkata, Ahmedabad) leverages locational advantages: Bangalore drives the lion’s share, Kolkata serves the SAARC corridor, and Ahmedabad connects to Eastern Africa.
• The build-up: Growth has been cultivated over two to three years through doctor visits, CMEs, outreach programs, and institutional tie-ups with insurance companies across the Middle East, Africa, and SAARC regions. Management is optimistic about sustaining the momentum.
• Digital patient engagement: A new customer app rolled out to nearly 8,000 unique patient IDs in Q1, offering functionalities the company claims are a first in the industry. The e-pharmacy platform serviced over 28,000 orders.
• Regulatory tailwind: A government circular now accepts regulatory approvals from the US, UK, Japan, Australia, and Canada for new drugs, removing the need for separate clinical investigations in India. Management flagged this as a milestone that will accelerate the channeling of new cancer drugs into the country.

Dr. B. S. Ajaikumar: "There has been some circular, which I read yesterday on the government has done away with requirements for clinical investigation for new drugs. And by this regulatory approval in US, UK, Japan, Australia, Canada is all that is needed. So, this is a very important milestone because new drugs can channel to India very quickly."

Competitive Positioning and Strategy

• Single-specialty focus as a moat: When asked about multi-specialty hospitals pulling share, management declined to compare directly, stating that HCG’s focus on oncology, innovation, and research has worked and will continue to work. Margins are progressing well, and the company does not worry about competitive intensity.
• Data-driven treatment differentiation: HCG is partnering with Accenture on computational work to identify the optimal treatment path for a specific patient with a specific cancer, aiming to treat the patient correctly the first time. Management frames this as a core differentiator.
• Inorganic pipeline: Management is evaluating inorganic opportunities but stated nothing is very mature at this point. Any deal would be strategic, and the market will be informed if and when something materializes.
• Promoter exit speculation: On questions about whether existing promoters might exit alongside the private equity investor CVC, Dr. Ajaikumar stated he has no intention of exiting and declined further comment, referring CVC-related questions to CVC themselves.

Raj Gore: "We don't necessarily think or too much worry about competition, focusing on oncology. What has worked for us? We believe that we will continue to work for us with our focus on innovation and research, and we would stay focused on it."

Guidance & Commitments

Key Metrics